Open access
Open access
Powered by Google Translator Translator

RCTs: Risankizumab as induction therapy for Crohn’s disease.

23 Jun, 2022 | 10:02h | UTC

Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials – The Lancet (link to abstract – $ for full-text)

Related: Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.